PPHM Share Price

Open 0.58 Change Price %
High 0.59 1 Day -0.01 -1.72
Low 0.57 1 Week -0.03 -5.00
Close 0.57 1 Month 0.00 0.00
Volume 746223 1 Year 0.18 46.15
52 Week High 0.77
52 Week Low 0.28
PPHM Important Levels
Resistance 2 0.59
Resistance 1 0.58
Pivot 0.58
Support 1 0.56
Support 2 0.55
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM)

PPHM Technical Analysis 1.5
As on 23rd Jun 2017 PPHM Share Price closed @ 0.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.45 & Sell for SHORT-TERM with Stoploss of 0.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
PPHM Target for June
1st Target up-side 0.63
2nd Target up-side 0.69
3rd Target up-side 0.75
1st Target down-side 0.47
2nd Target down-side 0.41
3rd Target down-side 0.35
PPHM Other Details
Segment EQ
Market Capital 78153800.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.peregrineinc.com
PPHM Address
PPHM
14282 Franklin Avenue
Tustin, CA 92780
United States
Phone: 714-508-6000
Fax: 714-838-5817
Interactive Technical Analysis Chart Peregrine Pharmaceuticals Inc. ( PPHM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Peregrine Pharmaceuticals Inc.
PPHM Business Profile
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. The Company is conducting three randomized Phase II trials for bavituximab in combination with standard chemotherapy for front and second-line non-small cell lung cancer and front-line pancreatic cancer. In addition to these company-sponsored trials for bavituximab, the Company has four investigator-sponsored trials looking at different treatment combinations and additional oncology indications.